Prostamax: KEDP molecular and prostate-use claims — RU2177802C1
В.Х. Хавинсон, В.В. Малинин, Е.И. Григорьев · 2002 · RU2177802C1 · patent family 20245158
Published 2002-01-10.
Reported patent results
Narrative findings; numerical extraction incomplete
The patent reports urinary-symptom improvement, but the displayed clinical percentages have incompletely specified denominators.
Prostamax/KEDP patent includes prostatitis observations and a prostate-adenoma comparison of 19 treated versus 17 conventional-care patients.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Prostatitis symptoms | Reported cessation of frequent urination in 87.5% and difficult urination in 80.7% | Narrative percentages; no verified responder counts inferred |
| Adenoma comparison | Subjective and urodynamic improvement reported; increased libido stated in 37.3% | 19 treated patients; 37.3% does not map cleanly to an integer count in this group |
Small incompletely reported comparisons, variable exposures and unclear percentage denominators prevent a reliable treatment effect. The molecular sequence is distinct from Prostatilen extract.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Molecule. The patent identifies Lys-Glu-Asp-Pro and proposed prostate-function applications.
This peptide is not a generic prostate extract or an unrelated supplement sold under a similar name.
- Publication
- RU2177802C1 ↗ · 2002-01-10
- Earliest priority / filing
- 2001-01-25 / 2001-01-25
- Original applicant / assignee
- Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20245158 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Tetrapeptide regulating prostate function, pharmacological agent based on thereof and method of its using
Inventors: В.Х. Хавинсон; В.В. Малинин; Е.И. Григорьев.
RU2177802C1 · EP1353939B1 · ATE274523T1 · AU2002221216A1 · DE60105204T2 · WO2002066497A2
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- This peptide is not a generic prostate extract or an unrelated supplement sold under a similar name.
- Small incompletely reported comparisons, variable exposures and unclear percentage denominators prevent a reliable treatment effect. The molecular sequence is distinct from Prostatilen extract.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20245158. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: В.Х. Хавинсон, В.В. Малинин, Е.И. Григорьев. Prostamax: KEDP molecular and prostate-use claims — RU2177802C1 RU2177802C1 · patent family 20245158 2002.
Molekul research summary: https://molekul.io/research/patent-ru2177802c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry